VKTX logo

Viking Therapeutics (VKTX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

28 April 2015

Indexes:

Not included

Description:

Viking Therapeutics is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. They aim to create new treatments for conditions like obesity and diabetes by advancing their drug candidates through clinical trials and research.

Events Calendar

Earnings

Next earnings date:

Feb 07, 2025

Recent quarterly earnings:

Oct 23, 2024

Recent annual earnings:

Feb 07, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

27 Nov '24 HC Wainwright & Co.
Buy
26 Nov '24 HC Wainwright & Co.
Buy
22 Nov '24 B. Riley Securities
Buy
05 Nov '24 HC Wainwright & Co.
Buy
24 Oct '24 HC Wainwright & Co.
Buy
09 Oct '24 HC Wainwright & Co.
Buy
25 Sept '24 Oppenheimer
Outperform
12 Sept '24 Morgan Stanley
Overweight
11 Sept '24 JP Morgan
Overweight
25 July '24 Raymond James
Strong Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
VKTX
benzinga.com29 November 2024

Viking Therapeutics Inc. (VKTX) is approaching an important point as its stock price is just above a possible death cross.

Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
VKTX
fool.com28 November 2024

Viking Therapeutics (VKTX 2.04%) is a hot biotech stock thanks to the company's record of reporting good data from its cardiometabolic disease programs, and there's no sign of that reputation being tarnished.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
VKTX
accesswire.com26 November 2024

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
VKTX
prnewswire.com25 November 2024

NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
VKTX
fool.com25 November 2024

Ken Griffin started the Citadel hedge fund in 1990. It's become so successful that his net worth has risen to a stunning $46 billion.

Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?
Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?
Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?
VKTX
zacks.com22 November 2024

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?

VKTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Viking Therapeutics, Inc.
VKTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Viking Therapeutics, Inc.
VKTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Viking Therapeutics, Inc.
VKTX
accesswire.com20 November 2024

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.

Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
VKTX
marketwatch.com20 November 2024

The biotech's liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.

3 Things You Need to Know if You Buy Viking Therapeutics Today
3 Things You Need to Know if You Buy Viking Therapeutics Today
3 Things You Need to Know if You Buy Viking Therapeutics Today
VKTX
fool.com18 November 2024

3 Things You Need to Know if You Buy Viking Therapeutics Today

Is It Too Late to Buy Viking Therapeutics Stock?
Is It Too Late to Buy Viking Therapeutics Stock?
Is It Too Late to Buy Viking Therapeutics Stock?
VKTX
fool.com17 November 2024

Is It Too Late to Buy Viking Therapeutics Stock?

FAQ

  • What is the primary business of Viking Therapeutics?
  • What is the ticker symbol for Viking Therapeutics?
  • Does Viking Therapeutics pay dividends?
  • What sector is Viking Therapeutics in?
  • What industry is Viking Therapeutics in?
  • What country is Viking Therapeutics based in?
  • When did Viking Therapeutics go public?
  • Is Viking Therapeutics in the S&P 500?
  • Is Viking Therapeutics in the NASDAQ 100?
  • Is Viking Therapeutics in the Dow Jones?
  • When was Viking Therapeutics's last earnings report?
  • When does Viking Therapeutics report earnings?
  • Should I buy Viking Therapeutics stock now?

What is the primary business of Viking Therapeutics?

Viking Therapeutics is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. They aim to create new treatments for conditions like obesity and diabetes by advancing their drug candidates through clinical trials and research.

What is the ticker symbol for Viking Therapeutics?

The ticker symbol for Viking Therapeutics is NASDAQ:VKTX

Does Viking Therapeutics pay dividends?

No, Viking Therapeutics does not pay dividends

What sector is Viking Therapeutics in?

Viking Therapeutics is in the Healthcare sector

What industry is Viking Therapeutics in?

Viking Therapeutics is in the Biotechnology industry

What country is Viking Therapeutics based in?

Viking Therapeutics is headquartered in United States

When did Viking Therapeutics go public?

Viking Therapeutics's initial public offering (IPO) was on 28 April 2015

Is Viking Therapeutics in the S&P 500?

No, Viking Therapeutics is not included in the S&P 500 index

Is Viking Therapeutics in the NASDAQ 100?

No, Viking Therapeutics is not included in the NASDAQ 100 index

Is Viking Therapeutics in the Dow Jones?

No, Viking Therapeutics is not included in the Dow Jones index

When was Viking Therapeutics's last earnings report?

Viking Therapeutics's most recent earnings report was on 23 October 2024

When does Viking Therapeutics report earnings?

The next expected earnings date for Viking Therapeutics is 7 February 2025

Should I buy Viking Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions